Biomet Settles Charges of Repeat FCPA Violations

Posted 2/8/17

Indiana medical device manufacturer Biomet Jan. 12, 2017, agreed to pay over $30 million to settle parallel charges of Securities and Exchange Commission (SEC) and Justice of violating the Foreign …

This item is available in full to subscribers.

Please log in to continue

Log in